The development and clinical evaluation of second-generation leishmaniasis vaccines.
about
Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic ReviewA review of preventative methods against human leishmaniasis infectionDifferences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discoveryCytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasisAsteraceae Artemisia campestris and Artemisia herba-alba Essential Oils Trigger Apoptosis and Cell Cycle Arrest in Leishmania infantum PromastigotesCross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal DomainsA third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.The Preventive Control of Zoonotic Visceral Leishmaniasis: Efficacy and Economic Evaluation.A canine model of experimental infection with Leishmania (L.) mexicanaHigh quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.Adjuvants for Leishmania vaccines: from models to clinical application.Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantumNeutrophils cast extracellular traps in response to protozoan parasites.Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 miceDifferential Role of Leptin as an Immunomodulator in Controlling Visceral Leishmaniasis in Normal and Leptin-Deficient Mice.The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas.Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis.Experimental models in vaccine research: malaria and leishmaniasis.Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.Development of a universal CTL-based vaccine for influenza.Therapeutic vaccines for leishmaniasis.Leishmania vaccine development: exploiting the host-vector-parasite interface.Overview of dendritic cell-based vaccine development for leishmaniasis.Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.Leishmania Uses Mincle to Target an Inhibitory ITAM Signaling Pathway in Dendritic Cells that Dampens Adaptive Immunity to InfectionRecovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection.Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania.Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates.[Leishmania epidemiology, diagnosis, chemotherapy and vaccination approaches in the international network of Pasteur Institutes].Dynamics of American tegumentary leishmaniasis in a highly endemic region for Leishmania (Viannia) braziliensis infection in northeast Brazil.Identification of Potential MHC Class-II-Restricted Epitopes Derived from Leishmania donovani Antigens by Reverse Vaccinology and Evaluation of Their CD4+ T-Cell Responsiveness against Visceral Leishmaniasis.To investigate the therapeutic potential of immunochemotherapy with cisplatin + 78 kDa + MPL-A against Leishmania donovani in BALB/c mice.In vitro antileishmanial and cytotoxicity activities of essential oils from Haplophyllum tuberculatum A. Juss leaves, stems and aerial parts.The role of LPD-nanoparticles containing recombinant major surface glycoprotein of Leishmania (rgp63) in protection against leishmaniasis in murine model.Mathematical modelling for Zoonotic Visceral Leishmaniasis dynamics: A new analysis considering updated parameters and notified human Brazilian data
P2860
Q26764786-A5AB555D-B617-426C-B82E-3E6817EC826EQ27305164-05D223A6-4940-41F8-9FE6-8B52369C0FE9Q28077110-A9C08BEB-C1D9-4B41-A822-00CF63CA82B0Q28485121-32EA4AA5-1458-48C9-BCB0-043CB6C5BCF1Q28821108-2043FD6B-EF13-4466-9ACC-9726023AC2E5Q33579979-BB9B0321-D40D-41A2-A06F-10EFB2613FA9Q33724960-7D48FB2E-D3BE-40B3-8C8E-8F7BADFC7BC5Q33735704-E7C6DD79-E696-4D68-8283-79B38E1FC1B2Q34067596-2FF5F8DE-0D5D-4950-B29A-58FF3E389E64Q34310410-3B36EFED-D6E3-493B-A738-10EC6CF1B8ECQ35809113-4DF53EB7-B43B-4777-9DD6-58D409954888Q36021357-4E8A6D35-DD76-43C5-B2B8-D1B7CD5F8706Q36331305-B3DFE0E0-94A5-4E14-8DDE-9B2373408DA1Q36465935-FED305D7-39EF-40F6-ACA9-6A030743E681Q36682576-9FC58F48-6D2D-4051-AFAD-23D8536E9414Q37094405-838CABC0-11B8-45F6-83F2-5D524CECD958Q37147622-9C7D9E49-7198-42AF-B50D-57991D7BD642Q37220949-4593BB60-CFFA-46FB-9AFD-33872A715B97Q37371348-EA5BCBBC-7929-4161-81A5-5014FBF9CFBDQ37434214-D4F70029-25B9-4D76-BAA0-FB3B1395D743Q38075677-EDA0E33B-91A9-4E58-B2C2-DB5933BDC40CQ38235456-F0DC9205-F980-42C7-A0D6-E1D7F6AD6C07Q38643410-A5BD279A-B96F-42A9-B2C7-AE9EC5D3B527Q38887861-5E3ABD4F-8E54-4515-B6B4-7A2529C0AA9EQ38947177-603F498C-2F00-4262-A50E-C117CCAD7589Q38962473-A16B17D6-FCAE-4A08-B501-DA2A53A5DC61Q39575305-D6631E6D-53D5-4C49-AE02-B552BA4311B6Q40499631-FD1DCF50-7299-4906-9A11-1D7D8D4F58BCQ40528471-D0F79454-A6FE-490E-8590-E9673071536CQ41146226-7F5DE622-533A-4ABA-A1B4-0F6ABA4FFA62Q41404819-04FB6296-A0D0-42C9-9506-4701DF08D18EQ41993713-55FE5A67-828E-4FD4-86BE-9A766A172DB5Q44872017-1457067B-E1D2-4569-BA42-491CE14532ECQ44920757-EF16B7F7-488B-4EE7-AAAB-68A1DDBCFCB2Q47201994-872C7295-BD73-4285-9511-49B5BC103FBCQ47732162-17D26297-B538-4884-80B8-9CBDE5F0717CQ49996455-C1D5787A-27A9-4988-B8D2-CDFA1339A686Q50054197-25E81887-E4BA-4397-AEFF-40373BADE3B2Q56892855-6BCDC412-8407-4C70-81CF-1DA9757E9E55
P2860
The development and clinical evaluation of second-generation leishmaniasis vaccines.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The development and clinical evaluation of second-generation leishmaniasis vaccines.
@ast
The development and clinical evaluation of second-generation leishmaniasis vaccines.
@en
type
label
The development and clinical evaluation of second-generation leishmaniasis vaccines.
@ast
The development and clinical evaluation of second-generation leishmaniasis vaccines.
@en
prefLabel
The development and clinical evaluation of second-generation leishmaniasis vaccines.
@ast
The development and clinical evaluation of second-generation leishmaniasis vaccines.
@en
P2860
P1433
P1476
The development and clinical evaluation of second-generation leishmaniasis vaccines
@en
P2093
Franco M Piazza
Vanitha S Raman
P2860
P304
P356
10.1016/J.VACCINE.2011.11.005
P407
P577
2011-11-12T00:00:00Z